Two weeks after Turing CEO Martin Shkreli promised to drop the price of his life-saving drug Daraprim, nothing has actually changed according to a report by Tech Insider.
The biotech leader came under fire last month after raising the price of a drug used to fight parasitic infections by a staggering 5,000%, rising from $13.50 to $750 seemingly overnight.
In September, Shkreli told ABC News, “We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit.”
According to Tech Insider, a 30-day, 30-pill supply of Daraprim would cost you $27,006 at your local pharmacy today. That boils down to about $900 a pill.
In comparison, cycloserine, a tuberculosis drug that The New York Times highlighted early on in the drug outrage, announced its new lowered price within a day of The Times’ Sunday article that was tweeted by Democratic presidential candidate Hillary Clinton.
Cycloserine, which was acquired by Rodelis Therapeutics from the Purdue Research Foundation (PRF) in August, jumped in price from $500 for 30 capsules to $10,800. After the article was published, the drug’s ownership was transferred back to PRF, and the price decreased to $1,050 for 30 capsules.
Speaking about his company’s decision to lower the price, PRF’s president, Dan Hasler, told The Times he’d only recently learned of Rodelis’ price hike on cycloserine, and added that “We said this was not what we had intended.”
Turing and Shkreli haven’t exactly been silent since the price-hike incident. Shkreli himself took to social media to defend his move. His company recently hired lobbyists — ostensibly to give them a hand in Congress, since Sen. Bernie Sanders (I-Vermont) and Rep. Elijah Cummings (D-Maryland) requested Turing provide them with information about the company by Friday, October 9.